Hansa Biopharma

Company snapshot

Hansa Biopharma, is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative and life altering treatments for patients with rare immunological conditions. Hansa scientists are working on developing immunomodulatory treatments for organ transplants, rare IgG-mediated autoimmune conditions, and gene therapy, as well as exploring the potential appli

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Hansa Biopharma. Not investment advice.

• deal Jun 2, 2026

  SERB Pharmaceuticals Acquires European and MENA Rights to Idefirix® (imlifidase) from Hansa Biopharma AB

• What is Hansa Biopharma?

  Hansa Biopharma AB is a biotech organization headquartered in Lund, SE. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (1).

• Is Hansa Biopharma publicly traded?

  Hansa Biopharma appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Hansa Biopharma develop or market?

  We link 4 drug profile(s) where Hansa Biopharma is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/hansa-biopharma-ab#company-drugs.

• What are the latest developments for Hansa Biopharma?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Hansa Biopharma focus on?

  No specific therapeutic focus areas are currently identified for Hansa Biopharma in our database.